Upcoming Earnings: Q2 '26
Estimated EPS
-$0.20
Estimated Rev
$1.38M
$NSPR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.16 up 27.27% YoY • Reported revenue of $3.4M up 122.24% YoY • InspireMD anticipates FDA approval for its original CGuard delivery system in Q3 2026 and CGuard Prime 80 cm for TCAR procedures in H2 2026, potentially doubling its addressable market.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.20 | -- | -- | N/A |
Q1 '26 | -$0.18 | -$0.16 | 11.11% | BEAT |
Q4 '25 | -$0.19 | -$0.14 | 27.59% | BEAT |
Q3 '25 | -$0.19 | -$0.17 | 12.82% | BEAT |
Q2 '25 | -$0.26 | -$0.26 | -- | EXPECTED |